Leerink Partnrs Analysts Decrease Earnings Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at Leerink Partnrs decreased their Q4 2024 earnings per share estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Monday, August 5th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will earn $1.38 per share for the quarter, down from their prior estimate of $1.42. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.23) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ FY2027 earnings at $1.50 EPS and FY2028 earnings at $2.55 EPS.

A number of other brokerages have also recently commented on ALDX. StockNews.com cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Oppenheimer reaffirmed an “outperform” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday, May 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday.

Aldeyra Therapeutics Stock Performance

Shares of ALDX traded up $0.91 during trading hours on Thursday, reaching $5.10. The stock had a trading volume of 2,333,130 shares, compared to its average volume of 504,526. Aldeyra Therapeutics has a 12 month low of $1.42 and a 12 month high of $7.88. The stock has a market capitalization of $303.01 million, a PE ratio of -10.00 and a beta of 1.45. The company’s 50-day moving average is $3.68 and its two-hundred day moving average is $3.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kennedy Capital Management LLC lifted its holdings in Aldeyra Therapeutics by 3.3% during the 1st quarter. Kennedy Capital Management LLC now owns 1,318,155 shares of the biotechnology company’s stock worth $4,310,000 after buying an additional 42,009 shares during the period. Federated Hermes Inc. bought a new position in shares of Aldeyra Therapeutics in the 2nd quarter worth about $1,758,000. Acadian Asset Management LLC raised its position in shares of Aldeyra Therapeutics by 106.3% in the 1st quarter. Acadian Asset Management LLC now owns 452,449 shares of the biotechnology company’s stock worth $1,478,000 after acquiring an additional 233,169 shares in the last quarter. PFG Investments LLC bought a new position in shares of Aldeyra Therapeutics in the 2nd quarter worth about $1,312,000. Finally, Los Angeles Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 240.9% in the 1st quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company’s stock worth $1,245,000 after acquiring an additional 269,061 shares in the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.